FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 20925 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Photodynamic Therapy Plus Topical Corticosteroid for Erosive Oral Lichen Planus: A Randomized Clinical Trial. PMID 41581340 · Int Dent J · 2026-Apr The study is a randomized controlled trial of a drug-containing intervention (photodynamic therapy combined with topical corticosteroid) with primary efficacy outcomes. However, it is excluded because it does not address a human malignant neoplasm (oral lichen planus is a non-malignant inflammatory condition) and lacks the required time-to-event efficacy endpoints. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Neoadjuvant therapy in skin cancer: current evidence and future perspectives. PMID 41580899 · J Dtsch Dermatol Ges · 2026-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Randomized comparative study of 5-Fluorouracil 4%, tirbanibulin, and photodynamic therapy for relapsing actinic keratoses. PMID 41580230 · Photodiagnosis Photodyn Ther · 2026-Apr The study is a randomized, human, oncology trial with drug intervention and original results, but it lacks a primary or key secondary time-to-event efficacy endpoint as required for eligibility. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Secondary outcomes of the TROG 99.03 randomized trial of systemic therapy after involved-field radiotherapy in early-stage follicular lymphoma, including toxicity, relapse and second malignancy data. PMID 41580147 · Radiother Oncol · 2026-Apr The record reports secondary outcomes of a randomized trial. While it includes a time-to-event efficacy endpoint (PFS with HR), the abstract and metadata do not explicitly state the trial phase (e.g., Phase III/IIIb). The deterministic review correctly identifies 'phase3_evidence_unclear'. Since the required criterion of a definitive Phase III/IIIb or Phase II/III phase is not explicitly established in the provided text, eligibility cannot be confirmed. The report is also a secondary analysis, not the primary result. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Test results and follow-up care stemming from an ED-based cervical cancer intervention. PMID 41579525 · Am J Emerg Med · 2026-Apr The study is a randomized trial of an ED-based cervical cancer screening intervention, not a drug intervention trial. It lacks the required Phase III/IIIb or Phase II/III drug trial structure and a primary time-to-event efficacy endpoint (like OS or PFS). |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Guselkumab Improves Patient-Reported Outcomes Among Participants with Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors in the COSMOS Study. PMID 41575731 · Rheumatol Ther · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| The effect of structured patient-to-patient communication on fear of cancer recurrence in total laryngectomy patients: A randomized controlled trial. PMID 41564457 · Auris Nasus Larynx · 2026-Apr The record describes a randomized controlled trial evaluating a non-drug intervention (patient-to-patient communication) for fear of cancer recurrence in laryngeal cancer patients. It meets oncology, human, and randomized criteria. However, it lacks a drug intervention and a time-to-event efficacy endpoint (like OS, PFS, etc.), which are required for inclusion. The primary endpoints are fear of cancer recurrence (FCRI scores) and swallowing-related quality of life (SWAL-QOL), which are patient-reported outcomes, not survival or time-to-event measures. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of concept. PMID 41559929 · Diabetes Obes Metab · 2026-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The Use of Durable Medical Equipment in COURAGE-ALS, a Phase 3, Multicentre, Randomized Clinical Trial for ALS. PMID 41553108 · Muscle Nerve · 2026-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Bronchial Arterial Chemoembolization Combined with Tislelizumab for Non-Small Cell Lung Cancer: An Exploratory, Prospective, Single-Arm, Phase II Trial. PMID 41548595 · J Vasc Interv Radiol · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| The Effect of a Water, Sanitation, and Hygiene Intervention on Clinical Trachoma: A Cluster-Randomised Trial. PMID 41548574 · Trop Med Int Health · 2026-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial. PMID 41544637 · Lancet Gastroenterol Hepatol · 2026-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Pembrolizumab for Early-Stage Triple-Negative Breast Cancer: KEYNOTE-522 Japan Subgroup Analysis. PMID 41536071 · Cancer Sci · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Impact of parenteral nutrition on oral intake and eating pleasure in advanced cancer patients: A sub-analysis of a multicenter randomized controlled trial. PMID 41534624 · Clin Nutr ESPEN · 2026-Apr The study is a randomized trial in advanced cancer patients, but it evaluates parenteral nutrition (a non-drug nutritional support) with oral intake and eating pleasure as endpoints. There is no drug intervention and no time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Validation of the Novel Pediatric Eosinophilic Esophagitis Sign/Symptom Questionnaire-Caregiver Version in EoE KIDS. PMID 41534558 · J Allergy Clin Immunol Pract · 2026-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Lp-PLA2 Activity and Genotype-Guided Dual Antiplatelet Therapy in Minor Stroke or Transient Ischemic Attack. PMID 41527826 · Stroke · 2026-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Novel immune-modulating formula versus standard formula for gastrointestinal cancer patients at risk of malnutrition undergoing surgery: A pilot randomized controlled trial. PMID 41525872 · Clin Nutr ESPEN · 2026-Apr The record describes a pilot RCT of a nutritional supplement in gastrointestinal cancer patients. It does not meet the criteria for a Phase II/III or III/IIIb drug trial with a time-to-event efficacy endpoint. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Two-Year Outcomes Following Delandistrogene Moxeparvovec Treatment in Ambulatory Patients with Duchenne Muscular Dystrophy: Phase 3 EMBARK Trial. PMID 41518520 · Neurol Ther · 2026-Apr 未发现恶性肿瘤人群证据。 |
H
|
仅历史库存 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Trajectory of Neurocognitive Functioning in Children Treated for Acute Lymphoblastic Leukemia (ALL): Dana-Farber Cancer Institute ALL Consortium Study 16-001. PMID 41518030 · Pediatr Blood Cancer · 2026-Apr The study is an oncology Phase III clinical trial in humans with a drug-containing intervention, but it lacks a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS with Kaplan-Meier or HR). The endpoint is neurocognitive functioning, which is a secondary/safety outcome, not a primary efficacy endpoint as required for inclusion. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Post Hoc, Sex-Specific Subgroup Analysis of Efgartigimod in Patients With Generalized Myasthenia Gravis From the ADAPT Trial: A Sex and Gender Equity in Research (SAGER) Guidelines Approach. PMID 41517964 · Muscle Nerve · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Impact of vascular endothelial growth factor inhibitor-induced hypertension on continued cancer treatment: a systematic review and meta-analysis. PMID 41501361 · Hypertens Res · 2026-Apr 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
B
|
仅广召回影子组 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy of Ixekizumab in Chinese Patients with Radiographic-Axial Spondyloarthritis by Baseline Inflammation Status on Magnetic Resonance Imaging. PMID 41495585 · Rheumatol Ther · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
|
仅历史库存 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Results of the Randomized Phase 3 AFU-GETUG-20 Trial Evaluating Adjuvant Leuprorelin Acetate After Radical Prostatectomy in Men with High-risk Localized Prostate Cancer. PMID 41486043 · Eur Urol Oncol · 2026-Apr 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Dazdotuftide: Novel Treatment for Noninfectious Uveitis with Superior Intraocular Pressure Safety Profile: A Randomized Clinical Trial. PMID 41485727 · Am J Ophthalmol · 2026-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| RESECT: A Randomised Controlled Trial of Audit and Feedback in Non-muscle-invasive Bladder Cancer Surgery. PMID 41444076 · Eur Urol · 2026-Apr The trial is oncology, human, randomized, and includes a drug intervention (single-instillation chemotherapy) with an original result. However, it is not a Phase III/IIIb or definitive Phase II/III trial (publication type is RCT but phase not specified, and study design is a cluster randomized quality improvement trial, not a drug efficacy trial). Furthermore, the primary endpoints are surgical performance metrics and early recurrence rate (reported as odds ratio), not a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, EFS, RFS, TTP) with Kaplan-Meier or HR. |
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Phase 3b Extension Study MT-1186-A04 to Evaluate the Continued Efficacy and Safety of Edaravone Oral Suspension for Up to an Additional 48 Weeks in Patients With Amyotrophic Lateral Sclerosis. PMID 41432316 · Muscle Nerve · 2026-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Efficacy, safety, pharmacokinetics, immunogenicity, and serum neutralizing activity of AZD7442 (tixagevimab-cilgavimab) in patients hospitalized with COVID-19: long-term results from the DisCoVeRy trial. PMID 41429349 · Clin Microbiol Infect · 2026-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| A cost comparison of radiotherapy and topical imiquimod for lentigo maligna treatment: Considerations for clinical decision-making. PMID 41421462 · J Am Acad Dermatol · 2026-Apr The record is a cost-comparison study based on a referenced Phase III randomized trial, but it is not a report of the trial's primary or key secondary time-to-event efficacy endpoint. The abstract focuses on economic outcomes, not survival or progression metrics. |
H
L
B
|
旧查询独有 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| [18F]-Fluciclovine or [68Ga]-PSMA-11 Molecular Imaging To Guide Dose Escalation of Salvage Radiotherapy After Radical Prostatectomy for Prostate Cancer: The EMPIRE-2 Trial. PMID 41412908 · Eur Urol · 2026-Apr The record describes a randomized trial with a primary time-to-event endpoint (EFS) in oncology. However, the intervention is [18F]-fluciclovine or [68Ga]-PSMA-11 for PET-guided radiotherapy dose escalation, which are radiopharmaceuticals used as imaging agents, not therapeutic drugs in the conventional sense of the cohort's definition of 'drug-containing intervention'. Furthermore, the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata, making the 'phase3_or_definitive' criterion unestablished. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes. PMID 41407860 · Nature · 2026-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Mazdutide versus placebo in Chinese adults with type 2 diabetes. PMID 41407859 · Nature · 2026-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Re: Niraparib and Abiraterone Acetate plus Prednisone for HRR-deficient Metastatic Castration-sensitive Prostate Cancer: A Randomized Phase 3 Trial. PMID 41407561 · Eur Urol · 2026-Apr The record describes a relevant Phase 3 randomized trial protocol but provides no reported results, including no time-to-event efficacy endpoint data, preventing classification as an eligible original result report. |
H
B
|
仅广召回影子组 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Avacincaptad Pegol for Geographic Atrophy Secondary to Age-Related Macular Degeneration: Two-Year Efficacy and Safety Results from the GATHER2 Phase 3 Trial. PMID 41407269 · Ophthalmology · 2026-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| The Value of Ultrasound in Patients with T1-T2 Breast Cancer with No Palpable Lymph Nodes Enrolled in the EORTC 10981-22023 AMAROS Trial. PMID 41392224 · Ann Surg Oncol · 2026-Apr The record describes a secondary analysis of the AMAROS trial focusing on the utility of axillary ultrasound. While it is from a Phase III randomized trial in oncology, the analysis is not a primary or key secondary efficacy report with a time-to-event endpoint. The intervention evaluated is a diagnostic procedure (ultrasound), not a drug. Therefore, it does not meet the criteria for inclusion in a Kaplan-Meier digitization cohort. |
H
L
B
|
旧查询独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Imlunestrant with or without abemaciclib in advanced breast cancer: updated efficacy results from the phase III EMBER-3 trial. PMID 41391667 · Ann Oncol · 2026-Apr 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Preventing gambling-related harm in adolescents (PRoGRAM-A), a secondary school-based social network intervention: Results from a pilot cluster randomised controlled trial. PMID 41388604 · Addiction · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Diagnostic Accuracy of [18F]FDG PET/CT versus CT for NSCLC Surveillance: Secondary Analysis of a Randomized Clinical Trial. PMID 41387040 · Clin Lung Cancer · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
B
|
仅广召回影子组 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Healthcare Utilization, Costs, and Cost-Effectiveness of Patients Undergoing Laparoscopic and Open Hemihepatectomy: A Secondary Analysis of the ORANGE II PLUS Randomized Controlled, Phase 3, Superiority Trial. PMID 41385067 · Ann Surg Oncol · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
B
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Durvalumab with carboplatin/paclitaxel and bevacizumab followed by durvalumab and bevacizumab with or without olaparib maintenance in newly diagnosed non-BRCA-mutated advanced ovarian cancer. PMID 41380962 · Ann Oncol · 2026-Apr 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Safety and immunogenicity of a live-attenuated chikungunya virus vaccine in adolescents: final results from a 12-month, double-blind, randomised, placebo-controlled, phase 3 trial in endemic areas of Brazil. PMID 41380703 · Lancet Infect Dis · 2026-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Hepatectomy Plus Chemotherapy or Chemotherapy Alone for Resectable Liver and Unresectable Lung Metastases from Colorectal Adenocarcinoma (LUNA): A Randomized Phase II Trial. PMID 41369813 · Ann Surg Oncol · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Trabectedin-olaparib combination or trabectedin in advanced soft tissue sarcomas after failure of anthracycline-based treatment (TOMAS2): a randomized phase II study from the Italian Sarcoma Group. PMID 41354211 · Ann Oncol · 2026-Apr 仅有 Phase I/II 证据,未达到确证性随机试验标准。 |
B
|
仅广召回影子组 | excludedearly_phase_only | pending 0 Figure · 0 Panel · risk - |
| Enzalutamide Monotherapy for the Treatment of Prostate Cancer With High-Risk Biochemical Recurrence: EMBARK Secondary End Points. PMID 41349040 · J Urol · 2026-Apr 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 1 Figure · 2 Panel · risk unclear |
| Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non-small-cell lung cancer: final analysis of the randomized RATIONALE-315 trial. PMID 41344593 · Ann Oncol · 2026-Apr 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Early adoption patterns of the recombinant zoster vaccine: real-world versus clinical trial populations. PMID 41335379 · Infect Dis (Lond) · 2026-Apr The study is a real-world observational analysis of vaccine uptake and population characteristics, not a clinical trial report. It is not in oncology, does not involve a drug intervention (it's a vaccine), and does not report a time-to-event efficacy endpoint from a randomized trial. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| The Effects of Nonintubated Anesthesia onNeutrophil-to-Lymphocyte Ratio and Tumor Markers Among Patients Undergoing Thoracoscopic Lung Resection: A Randomized Controlled Trial. PMID 41320620 · J Cardiothorac Vasc Anesth · 2026-Apr The study is a randomized trial on lung cancer patients, but it evaluates an anesthesia technique (nonintubated vs. traditional) with outcomes focused on inflammatory biomarkers (NLR) and surgical/clinical metrics. It does not involve a drug-containing intervention or a time-to-event efficacy endpoint (e.g., OS, PFS). Therefore, it does not meet the eligibility criteria for the oncology KM digitization cohort. |
B
|
仅广召回影子组 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial. PMID 41317911 · J Am Acad Dermatol · 2026-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Maintenance of long-term efficacy with continuous baricitinib treatment in patients with severe alopecia areata: 3-year results from BRAVE-AA1 and BRAVE-AA2. PMID 41314424 · J Am Acad Dermatol · 2026-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Pharmacokinetics and pharmacodynamics of AQST-109: Phase 3 results comparing epinephrine sublingual film with intramuscular injection. PMID 41297629 · Ann Allergy Asthma Immunol · 2026-Apr 未发现恶性肿瘤人群证据。 |
H
L
|
旧查询独有 | excludednon_oncology | pending 0 Figure · 0 Panel · risk - |
| Endoscopic Response to Subcutaneous Infliximab by Disease Location: A Post Hoc Analysis of the LIBERTY-CD Study. PMID 41285264 · Clin Gastroenterol Hepatol · 2026-Apr 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
|
旧查询独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |